Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Cancer Res. 2015 Dec 9;22(7):1572–1582. doi: 10.1158/1078-0432.CCR-15-1965

Table 1.

Patient Characteristics

Trial arm subgroup n= sex (M), % Rai ≥3, % Unmut, % CD38+, %
≥65 TN 17 53 59 53 24
≥65 RR 16 50 81 81 56
TP53 TN 33 64 61 64 27
TP53 RR 14 50 79 71 36
Both all 80 56 68 66 34

≥65: 65 years of age or older, TP53: TP53 aberrations, TN: treatment naïve, RR: relapsed or refractory, M: male, Unmut: unmutated IGHV (>98% homology to germline), CD38+: >30% of CLL cells express CD38 above isotype control.